Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Interest & Investment Income (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Interest & Investment Income for 9 consecutive years, with $6.8 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 1.34% to $6.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.8 million through Dec 2025, up 9.4% year-over-year, with the annual reading at $28.8 million for FY2025, 9.4% up from the prior year.
  • Interest & Investment Income hit $6.8 million in Q4 2025 for Protagonist Therapeutics, down from $7.0 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.7 million in Q3 2024 to a low of $97000.0 in Q2 2021.
  • Historically, Interest & Investment Income has averaged $3.7 million across 5 years, with a median of $4.1 million in 2023.
  • Biggest five-year swings in Interest & Investment Income: crashed 80.61% in 2021 and later soared 1745.08% in 2022.
  • Year by year, Interest & Investment Income stood at $122000.0 in 2021, then skyrocketed by 1745.08% to $2.3 million in 2022, then surged by 88.45% to $4.2 million in 2023, then skyrocketed by 61.55% to $6.9 million in 2024, then decreased by 1.34% to $6.8 million in 2025.
  • Business Quant data shows Interest & Investment Income for PTGX at $6.8 million in Q4 2025, $7.0 million in Q3 2025, and $7.4 million in Q2 2025.